Neurocrine Biosciences (NBIX) EBIT Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | -59.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.21% |
| Mar 31, 2026 | 54.58% |
| Dec 31, 2025 | 26.82% |
| Sep 30, 2025 | 39.63% |
| Jun 30, 2025 | 38.59% |
| Mar 31, 2025 | 96.72% |
| Dec 31, 2024 | 80.82% |
| Sep 30, 2024 | 60.45% |
| Jun 30, 2024 | 32.29% |
| Mar 31, 2024 | 46.63% |
| Dec 31, 2023 | 27.92% |
| Sep 30, 2023 | 73.11% |
| Jun 30, 2023 | -1.32% |
| Mar 31, 2023 | -57.93% |
| Dec 31, 2022 | 28.44% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 16.72% |
| Mar 31, 2022 | 26.63% |
| Dec 31, 2021 | -54.21% |
| Sep 30, 2021 | -6.43% |